Zai Lab Ltd.
Division of ZAI Lab Ltd.
Latest From Zai Lab Ltd.
The JVs will develop and commercialize therapeutics for multiple cancer types and autoimmune disorders in China. Novocure partners its Tumor Treating Fields technology with Zai Lab, while Fate and ONO will collaborate on off-the-shelf CAR-T therapies.
AstraZeneca/Merck & Co’s Lynparza has become the first PARP inhibitor to be approved in China, continuing a recent trend of accelerated reviews and approvals for novel therapies from multinationals in the country.
The coming of June has brought new executives at Daiichi Sankyo, UCB, ViiV in Japan and ZAI Lab in China.
As it narrows focus to core therapeutic areas ahead of acquiring Shire, Takeda sends uterine fibroid and endometriosis rights to compatriot firm ASKA. Zai Lab and Crescendo team up on antibody candidate for inflammatory indications.
- Therapeutic Areas
- Immune Disorders
- Respiratory, Pulmonary
- ZAI Laboratory Inc.
- Company Type
- Parent & Subsidiaries
- ZAI Lab Ltd.
- Senior Management
Samantha Du, PhD, Chmn. & CEO
Billy Cho, CFO
Jonathan Wang, VP, Head, Bus. Dev.
William Liang, Chief Commercial Officer
- Contact Info
Zai Lab Ltd.
Phone: 21 6163 2588
4560 Jinke Rd., Jinchuang Plaza Bldg. 1
Pudong, Shanghai, 201210
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.